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Abstract  
Introduction: Diagnostic guidelines for Tuberculosis (TB) in HIV infected patients previously relied on microscopy where the value of initial 
antibiotic treatment for exclusion of pulmonary TB (PTB) was limited. New guidelines rely on the Xpert MTB Rif test (Xpert). However, the value of 
the antibiotic treatment remains unclear particularly in individuals who are smear-negative and Xpert-negative-given Xpert has only moderate 
sensitivity for smear-negative PTB. We assessed an algorithm involving initial treatment with antibiotics prior empiric TB treatment in HIV patients 
with presumptive PTB who were both smear and Xpert negative. Methods: We performed a prospective study with six month follow-up to 
establish patient response to a course of broad spectrum antibiotics prior empiric TB treatment between March 2012 and June 2013. We calculated 
the proportion of patients who responded to the antibiotic treatment and those who did not. We computed the crude and adjusted odds ratios with 
their 95% confidence intervals, for response to the antibiotic treatment on various patient characteristics. We report treatment outcomes for 
patients who received broad spectrum antibiotics only or who were initiated empiric TB treatment. Results: Our cohort comprised 162 smear-
negative and Xpert-negative patients, of whom 59% (96 of 162) were female, 81% (131 of 162) were on antiretroviral therapy (ART) for a median 
of 8.7 months. Overall, 88% (141 of 160) responded to the antibiotic treatment, 8% (12 of 160) got empiric TB treatment and 4% (7 out of 160) 
were treated for other respiratory disease. The odds of improvement on antibiotics were lower in patients with advanced HIV disease than in 
patients with early HIV disease. Adjusted odds ratios were significant for HIV clinical stage (AOR; 0.038,) and duration on ART (AOR; 1.038,). 
Conclusion: The majority of HIV patients with presumptive PTB with smear-negative and Xpert negative results improved on the antibiotic 
treatment and did not require empiric TB treatment. Initial antibiotic treatment appeared more successful in patients with less advanced HIV 
disease. Findings from our study suggest it is useful to initiate HIV infected patients with presumptive PTB having smear and Xpert negative results 
on an initial course of antibiotic treatment prior empiric TB treatment. 
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Introduction 
 
Tuberculosis (TB) with HIV co-infection is highly prevalent in sub-
Saharan Africa, accounting for seventy-five percent of HIV-
associated TB globally [1]. Traditionally, TB diagnosis in the region 
relies on sputum smear microscopy. However, TB microscopy 
misses many patients especially if they are infected with HIV [2]. 
Thus, smear-negative TB is a common clinical problem and the 
practice of empiric TB treatment is equally common [3, 4]. Since 
2010, the World Health Organization (WHO) has recommended 
Xpert MTB/RIF test (Xpert) as the primary diagnostic for HIV-
associated TB or where resources are limited, as a follow-on test to 
TB microscopy. Xpert has been scaled-up in numerous global 
settings since that time [5, 6]. However, Xpert has only moderate 
(67%) sensitivity for smear-negative pulmonary TB and a negative 
Xpert result is insufficient therefore to rule out active pulmonary TB 
(PTB) [7, 8]. Existing clinical algorithms for management of 
ambulatory Xpert negative patients include further investigation for 
other aetiologies of respiratory disease or extra-pulmonary TB 
(EPTB) with the assistance of quality chest X-ray, repeat Xpert or 
culture [9, 10]. These algorithms however, are lengthy to 
implement, requiring patients to make three or more visits with high 
potential for patient drop-out during the diagnostic process [11]. 
Furthermore, quality chest X-ray is not accessible in many peripheral 
or even referral health facilities. But even when chest X-ray is 
performed, it does not provide a microbiological diagnosis of TB and 
cannot therefore, be relied upon for a definitive diagnosis of the 
disease [12]. On the other hand, Mycobacterial culture is 
undertaken at central level laboratories and results are seldom 
available in a clinically relevant timeframe [13]. While a repeat Xpert 
test although attractive, is currently very expensive to implement in 
routine patient care [14]. Thus, clinicians in settings where TB-HIV 
co-infection is prevalent, still face the dilemma of what to do with 
smear-negative and Xpert negative patients. Commonly, they treat 
such patients for TB on basis of clinician decision [15, 16]. In the 
era when TB diagnostic algorithms relied primarily on microscopy, 
the value of antibiotic treatment in HIV patients with presumptive 
TB was limited as response to the antibiotics did not exclude TB 
[17]. While several studies have researched the diagnostic accuracy 
of the Xpert, there is limited evidence for the use of antibiotic 
treatment in the diagnosis process of TB in the era of Xpert [18]. In 
this study, we report on outcomes in our setting in Uganda, 
following the implementation of an algorithm to manage HIV-
infected individuals with presumptive TB who were smear-negative 
and Xpert-negative. The algorithm involved initial treatment with 
broad spectrum antibiotics prior a decision to initiate empiric TB 
treatment. This strategy was previously used before to increase 
diagnostic accuracy of TB in high HIV prevalent settings [19]. Since 
the Xpert has moderate sensitivity for smear-negative TB which is 
common in this patient group, the question of response to initial 
antibiotic treatment is an important one to study in settings with 





Study design and setting 
  
This prospective cohort study was conducted at the Mulago-Immune 
Suppression Syndrome (Mulago-ISS) clinic which is located at the 
campus of Mulago National Referral Hospital in Kampala, Uganda. 
The clinic is a doctor led outpatient HIV care facility supported by 
the Makerere University Joint AIDS Program (MJAP). Since 2004, the 
clinic was funded by the U.S. President's Emergency Plan for AIDS 
Relief (PEPFAR) to provide comprehensive HIV care services 
including TB, to adults and children at no charge. The HIV care 
services provided at the clinic include HIV counselling and testing, 
treatment of HIV related complications, laboratory testing 
(confirmatory HIV-1 testing, complete blood count and CD4 
lymphocyte count), co-trimoxazole prophylaxis, and anti-retro-
therapy (ART) according to the World Health Organization and the 
Uganda Ministry of Health guidelines. Tests for CD4 lymphocyte 
count were performed routinely for each patient every six months 
using a FACS Calibur machine (Becton Dickinson, Franklin Lakes, NJ, 
USA). At the time of the study, tests for viral load monitoring were 
not performed routinely and were only done in patients suspected of 
virological failure based on clinical and immunological grounds. As of 
March 2012, 14,000 patients were receiving HIV care at the clinic. 
Initiation of ART was done for all HIV infected individuals with a 
diagnosis of AIDS (HIV clinical stage IV disease) or a CD4 count < 
350 cells/mm3 or HIV with TB co-infection or HIV with active - 
Hepatitis B infection or HIV associated nephropathy. During the 
study period, an infection control nurse used a Ministry of Health 
"Intensified TB Case Finding Form" to screen all patients for TB 
symptoms (cough for two weeks or more, or persistent fevers for 
two weeks or more, or noticeable weight loss in last one month or 
excessive night sweats for three weeks or more) as they waited in 
the seating area 
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Patient selection 
  
Participants included consecutive HIV infected patients presenting 
with presumptive PTB who were smear-negative after fluorescent 
TB microscopy (FM) between March 2012-June 2013 inclusive of 
recruitment and final assessment. Participants fulfilled the following 
criteria: confirmed HIV-1 infection; age ≥ 18 years; cough ≥ 2 
weeks or fevers ≥ 2 weeks or noticeable weight loss or excessive 
night sweats ≥ 3 weeks. Patients who were smear-negative and 
Xpert negative were enrolled into the study. We excluded patients 




Participants provided a spot and early morning sputum sample 
which were examined by FM. Samples which were FM negative 
(smear-negative) were examined further using a one-off Xpert test 
and combined solid and liquid TB culture as part of a research 
procedure [20]. If the Xpert test was positive, TB treatment was 
initiated. Patients whose Xpert test results were negative for TB 
were treated with oral broad spectrum antibiotics using macrolides 
such as azithromycin, or cephalosporins such as cefuroxime. We did 
not use quinolones as they used to treat TB. Patients were asked to 
return for review after two weeks or earlier if their symptoms 
worsened. At review, the clinical status of the patients was assessed 
to establish response (reported by patients as absence or presence 
of symptoms) to the antibiotic treatment. If the patient did not 
respond to the antibiotic treatment, other investigations when 
present, such as chest X-ray or abdominal ultra-sound or 
microscopy exam of lymph node aspirate or biopsy were done to 
exclude EPTB and other etiologies of respiratory disease. Patients 
diagnosed with other respiratory diseases were referred to specialist 
clinics in the hospital and no further follow-up was done. If no other 
diagnosis was made, the patients were initiated on standard anti-TB 
treatment empirically. This comprised an initial phase of two months 
of daily rifampicin, isoniazid, pyrazinamide and ethambutol (all the 
Xpert negative patients were presumed to be susceptible to 
Rifampicin), followed by a four months continuation phase of daily 
rifampicin and isoniazid at a specialized out-patient TB/HIV clinic. 
Patients were reviewed after two weeks initially and every 4 weeks 
subsequently to monitor clinical status and adherence to treatment. 






We defined the baseline CD4 lymphocyte counts as those that were 
recorded closest to the date when patients were enrolled into the 
study, with a maximum of 6 months prior. Response to antibiotic 
treatment was reviewed each month and was defined as being 
symptom free at six months after the course of antibiotic treatment. 
Response to empiric TB treatment was defined as being symptom 
free at six months following initiation of the TB treatment. Duration 
on ART was defined as the period from the date of initiation of ART 
at MJAP to the date when the patient was enrolled into the study. 
Patients were defined as lost to follow-up if they did not attend the 
clinic for more than 90 days from the day the patient's sputum 
sample was collected. Individuals recorded as dead in the patient 




A standardized data collection form was used to collect individual 
patient data at presentation (baseline) and at month six. Socio-
demographic data: comprised gender, age, education level, 
employment status and marital status. Clinical data comprised: 
baseline CD4 lymphocyte cell, HIV clinical stage, ART treatment 
status and duration if on ART, history of previous TB treatment and 
the diagnosis on review at week two. Laboratory data: comprised 
Xpert test result and TB culture test result. Treatment outcome data 
comprised: response, no-response, lost-to-follow-up, or dead upon 




The mean and median were used to summarize numerical data. 
Frequencies and proportions were used to summarize categorical 
data. The T-test was used to compare normally distributed 
numerical data and the Mann-Whitney rank-sum test was used to 
compare non-normally distributed numerical data. The Chi-squared 
or Fisher's exact tests were used to compare categorical data. We 
compared the odds of response to antibiotics to the odds of no-
response to the antibiotics (inclusive of those diagnosed with other 
respiratory diseases) to obtain crude odds ratios for each patient 
characteristic. Multivariate logistic regression using the crude odds 
ratios was performed to obtain adjusted odds ratios for 
characteristics with p values of less than 0.2 and those with a 
biological plausibility to influence response to antibiotic treatment. 
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Ethical considerations 
  
The Uganda national Council for Science and Technology provided 





General patient characteristics 
  
A total of 162 smear-negative and Xpert-negative patients were 
enrolled. Their general characteristics are summarized in Table 1. Of 
the cohort, 59% (96 of 162) were female. The mean age was 38 
years (SD ± 10), the median CD4 lymphocyte count was 293 
cells/µL (IQR: 129-455), and 81% (131 of 162) were on ART at 
enrolment. The median duration on ART was 8.7 months (IQR: 2.9-
30.3). A small majority, 56% (90 of 162) were in late HIV clinical 
stage (III and IV). Other socio-demographic characteristics are 
presented in the table. Of the 162 smears and Xpert negative 
patients, 99% (160 of 162) received broad spectrum antibiotics 
while treatment data was unavailable for two (Figure 1). Among 
these, 88% (141 of 160) responded to the treatment. Conversely, 
12% (19 of 160) did not respond the treatment. Of the 19 who did 
not respond to the antibiotic treatment, seven were diagnosed with 
other respiratory illnesses (Kaposi sarcoma-one, bronchial-alveolar 
carcinoma-one and chronic obstructive pulmonary diseases-five) 
while twelve got empiric TB treatment to which the majority (11 of 
12) responded. As shown in Table 2, the odds of improvement on 
antibiotics were not significant with any of the socio-demographic or 
clinical variables tested except for stage of HIV. The odds were 
lower (0.05) and statistically significant in patients with advanced 
HIV disease than in patients with early HIV disease (OR 0.05; 95% 
CI 0.0-0.42). The significance was retained in a multivariate model 
(Table 3). Of the cultures requested, reports were provided for 68% 
(110/162) of the patients. Nearly all the missing reports were for 
patients who received antibiotic treatment only. The culture reports 
were negative for TB in all patients who responded to antibiotic 
treatment and in patients diagnosed with other respiratory illnesses. 
Of the twelve patients who got empiric TB treatment, only one was 
culture positive, eight were culture negative and three were 
undetermined because the cultures were either contaminated or the 





We studied outcomes following the implementation of a simple 
algorithm to manage smear-negative and Xpert-negative HIV 
patients with presumptive PTB in a routine HIV clinical setting with 
limited TB diagnostics. This involved treatment for bacterial 
infection, clinical assessment if there was no response, and followed 
by empiric TB treatment. The majority (88%) of the patients 
responded to treatment for bacterial infection with only a few (8%) 
getting empiric TB treatment. Our study suggests, that a negative 
smear and Xpert had a very high negative predictive value for PTB 
in our clinic (only one culture positive case out of 110). Treatment 
with broad spectrum antibiotics could therefore be useful to exclude 
TB in HIV patients in our setting. In our study, treatment for 
bacterial infection appeared to be useful in individuals with CD4 cell 
count > 350, or in early stage HIV disease (and therefore not 
eligible for ART) although some of this lost significance in 
multivariate analysis. Conversely, in individuals with CD4 cell count 
≤ 350, or in late stage HIV disease (and therefore eligible for ART), 
undiagnosed TB remained a possibility despite a negative smear and 
Xpert result and such patients benefited from the empiric TB 
treatment. When we compared the clinicians' decisions to initiate 
empiric TB treatment with TB culture results, only one of twelve 
patients had culture confirmed disease. The decision to initiate TB 
treatment in these patients therefore poorly correlated with the 
culture results as reported previously [3]. However this level of 
empiric TB treatment was comparable to that in a study from South 
Africa where 11% of HIV patients with presumptive TB and Xpert 
negative results also got treated for TB empirically [21]. It is likely 
that the patients in our study whose cultures were negative had 
very few TB bacilli in their clinical samples. The viability of these 
bacilli could have been reduced or some even killed by the 
procedures involved in processing the samples for TB culture [22]. 
This possibility was supported by a sub analysis of the data from our 
diagnostic accuracy study of Xpert which revealed nearly half of 
samples with very low MTB detected results, had cycle threshold 
values of thirty or more and negative TB culture results [20]. While 
there are concerns about the use of antibiotic treatment as a 
diagnostic aid because of treatment delay and antibiotic resistance 
particularly for TB [23], the benefits of antibiotic treatment could 
outweigh the risks because of reduced empiric TB treatment and the 
associated adverse consequences of the practice such as; drug 
toxicity, long treatment duration and increased possibility of 
generating multi drug-resistant TB. Moreover, patients are more 
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likely to complete short-course antibiotics regimens as prescribed, 
which is one strategy to decrease antibiotic resistance [24]. In 
addition, the effectiveness of the antibiotics could be maintained if 
they are chosen wisely. For example, in our study, we excluded the 
use of quinolones because they are used in second line treatment 
for TB, and their routine use is associated with delayed treatment 
and resistance in TB [25]. To facilitate wise choice of the antibiotics, 
clinicians need to follow existing recommendations to prescribe 
fewer broad spectrum antibiotics based on standard treatment 
guidelines. These guidelines in turn need periodic and regular 
review using data from surveillance of bacterial resistance and 
antibiotic use [26]. 
  
Our strategy could be useful in our setting or similar other settings 
because laboratories may not cope with the influx of clinical 
specimens for both TB diagnosis and follow-up examinations. This 
strategy could therefore save resources, that would otherwise be 
consumed by performing additional tests and procedures for 
patients in whom the majority would eventually not have TB as 
shown by one study from the same study area [27]. This study and 
another recent one, showed that the common bacterial infections in 
HIV patients, are susceptible to broad spectrum antibiotics and 
therefore are useful in routine patient care [28]. Moreover, it was 
shown also, that the early clinical consequences of false-negative 
Xpert tests were not grave and that rapid empiric TB treatment may 
not be necessary in patients with Xpert negative results [21]. Our 
strategy involved two clinic visits by patients before the decision to 
treat for TB was taken. Few patients (3 out of 162) were not 
accounted for in the diagnostic pathway meaning the strategy could 
be feasible. This is useful because lengthy algorithms are poorly 
implemented by clinicians and are associated with high patient loss-
to-follow-up and poor patient outcomes [11, 29]. Our study was 
done in a setting where Xpert had a high negative predictive value 
(those who were negative by Xpert were unlikely to have PTB) and 
therefore, cure from a course of antibiotics was high. The results 
are only applicable to similar settings where Xpert has a high 
negative predictive value. We acknowledge the small size of our 
study, which could result in inconsistent measures of association. 
Second, we studied a highly selected out-patient HIV population 
where the majority (81%) of the individuals were on ART compared 
to 62% in the general adult population in Uganda setting [30]. 
These results may therefore not be generalized to hospitalized 
patients or to populations where ART coverage is low. Third, our 
findings could also be cofounded by co-morbidities such as smoking 
status, diabetes, adherence to the prescribed medicines or baseline 
CD4 versus CD4 counts at six months, which we did not analyse as 
these data were not collected. Other predictive factors not collected 
included symptom intensity, haemoglobin concentration, serum C-
reactive protein and body mass index, Therefore, the range of 
possible factors influencing patient outcomes in our study was not 
exhaustive. Fourth, we did not ascertain if the patients whose 
cultures were contaminated and were empirically treated for TB, did 
not actually have disease. Additional sample collection and culture 
would have been useful to confirm if they had TB or not. However, 
the results were not received in time to collect another sample 





The majority of HIV patients with presumptive PTB with smear-
negative and Xpert negative results in our clinic setting improved on 
the antibiotic treatment and did not require empiric TB treatment. 
Initial antibiotic treatment appeared more successful in patients with 
less advanced HIV disease. Findings from our setting suggest it is 
useful to initiate HIV infected patients presenting with presumptive 
smear negative PTB on an initial course of antibiotic treatment. 
 
What is known about this topic 
 The Xpert MTB/RIF test (Xpert) detects about 80% of 
pulmonary TB cases in people living with HIV (PLHIV). 
 Xpert also improves the quality and turnaround time for 
TB diagnosis among PLHIV who are smear microscopy 
negative. 
 However, when PLHIV are both smear and Xpert 
negative, the role of empiric TB treatment is unclear in 
settings where additional investigations for TB are limited. 
 
What this study adds 
 In this study, we show that routine practice of empiric TB 
treatment, in PLHIV who are both smear and Xpert 
negative is un-necessary. 
 Majority of such patients respond fully to broad spectrum 
antibiotic treatment that covers typical and atypical 
bacteria. 
 Empiric TB treatment only appears necessary when 
targeted at individuals in HIV clinical stage 3 and 4, after 
close follow-up. 
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Age: years, mean, (SD) 38 (10) - 
Males 66 41 
Females 96 59 




      - 
HIV Early Clinical Stage 
(1&2) 
72 44 
HIV Late Clinical Stage 
(3&4) 
90 56 
On ART   131 81 
Not on ART 31 19 






Had previous TB treatment 24 15 
No previous TB treatment 138 85 
Primary education level 
and below 
102 63 
Secondary education level 
and above 
60 37 
Not employed 20 12 
Employed 142 88 
Never married 13 8 
Married 88 54 
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Table 2: Patient characteristics compared by response to antibiotics 









Age: years, mean, (SD) 38, (9.9) 38, (11) 0.99 (0.95-1) 0.991 
Males, no. (%) 57, (40) 7, (37) 
0.86 (0.31-2.3) 0.765 
Females no. (%) 84, (60) 12, (63) 
CD4 count ≤350 cells/µL, n (%) 83, (59) 13, (68) 
1.5 (0.5-4.2) 0.427 
CD4 count >350 cells/µL, n (%) 58 (41) 6, (32) 
HIV Early Clinical Stage (1&2) n, (%) 71, (50) 1, (5) 
0.05 (0.0-0.42) 0.005 
HIV Late Clinical Stage (3&4) n, (%) 70, (50) 18, (95) 
On ART, n, (%) 112, (79) 17, (89) 
2.2 (0.48-10) 0.309 
Not on ART, n (%) 29, (21) 2, (11) 





(4.6 – 10.4) 
1 (0.99-1.06) 0.096 
Had previous TB treatment, no, (%) 21, (15) 3, (16) 
1.1 (0.29-4) 0.918 
No previous TB treatment, no, (%) 120, (85) 16, (84) 
Primary education and below, no, (%) 88 (62) 12 (63) 
1 (0.38-2.78) 0.950 Secondary education and above, no, 
(%) 
53 (38) 7 (37) 
Not employed, no, (%) 16 (11) 4 (21) 
2.1 (0.62-7.05) 0.238 
Employed, no, (%) 125 (89) 15 (79) 
Never married, no, (%) 12 (9) 1 (5) 1 - 
Married no, (%) 79 (56) 8 (42) 0.82 (0.09-7.18) 0.860 




Table 3: Adjusted odds ratios of patient characteristics for response to 
antibiotics 
Parameter Crude odds 
ratio (95% CI) 
p-value Adjusted odds ratio 
(95% CI) 
p-value 
Age 0.99 (0.95-1) 0.991 0.978 (0.930 - 1.028) 0.381 
Gender 0.86 (0.31-2.3) 0.765 0.760 (0.251 - 2.299) 0.627 
CD4 cell count 1.5 (0.5-4.2) 0.427 0.668 (0.171 - 2.618) 0.563 
HIV clinical 
stage 
0.05 (0.0-0.42) 0.005 0.038 (0.005 - 0.307) 0.002 
ART status 2.2 (0.48-10) 0.309 5.016 (0.699 - 36.001) 0.109 
Duration on ART 1 (0.99-1.06) 0.096 1.038 (1.003 - 1.074) 0.032 
Previous TB 
treatment 
1.1 (0.29-4) 0.918 0.577 (0.139 - 2.393) 0.448 
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Figure 1: Study flow and patient treatment outcomes 
 
